Orchid Cellmark's Q3 Revenues Drop on Lower UK Sales | GenomeWeb
NEW YORK (GenomeWeb News) – Orchid Cellmark’s third-quarter revenues declined around 4 percent year over year due to lower service revenues in the UK.
 
The Princeton, NJ-based DNA testing services firm reported revenues of $14.9 million for the three-month period ended Sept. 30, compared with revenues of $15.6 million in the comparable period of 2007. A decline in UK revenues was partially offset by a 4 percent increase in US revenues during the quarter, the firm said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.